by clicking the arrows at the side of the page, or by using the toolbar.
by clicking anywhere on the page.
by dragging the page around when zoomed in.
by clicking anywhere on the page when zoomed in.
web sites or send emails by clicking on hyperlinks.
Bio Technology : July 2009
AusBioPEOPLE Biofiba Technologies Limited is an unlisted Public Company founded on 18th March 2009 to commercialise and exploit the Biofiba Technology (patents pending). BiofibaTM is a simulated synthetic composite material developed as an alternative environmentally acceptable replacement for timber and wooden section used to manufacture one way one use export shipping pallets. BiofibaTM VIRAX HOLDINGS LIMITED Virax is developing novel immunotherapeutic products based upon its Co-X-GeneTM technology. has a potential to capture not less than 3% of the annual export pallet market (USD2.25 billion dollars) within 2 years from commercialisation. The company will further investigate and capitalise upon other markets once the initial market has been established. Contact: Corporate Headquarters Biofiba Technologies Limited 93A Albany Street, Point Frederick NSW, 2250, Australia Tel: +61 2 4325 7788 Fax: +61 2 4324 8479 Email: email@example.com Website: www.biofiba.com The Co-X-GeneTM based therapeutic vaccines in clinical development are: • • • HIV (VIR201) – Phase I/IIa *HPV dependent pathologies (TG4001) – Phase II *Lung cancer (TG4010) – Phase IIb *Virax has licensed the Co-X-GeneTM technology to Transgene SA for these cancer applications. VIR201 has demonstrated potential anti-virological efficacy in previous clinical testing. The current VIR201 clinical trial is externally funded. Virax also has milestone revenue stream via its Transgene license. Virax is seeking consolidation partners with complementary vaccine or biologics assets and/or revenue streams to build a leading therapeutics franchise. Dr Larry Ward Chief Executive Officer Virax Holdings Ltd Suite 220, Kew Junction Tower 89 High St., Kew Vic 3101, Australia Tel: + 61 3 98546230 Fax: + 61 3 9853 5134 Website: http://www.virax.com.au Cullen & Co. With 73 years of experience, Cullen & Co. is Queensland’s longest established and largest firm of intellectual property specialists. Cullen & Co. helps clients devise a protection strategy to enable security of their assets as they become a commercial viability. We provide intellectual property protection for clients in over one hundred countries. Our experienced life science, pharmaceutical and chemistry attorneys have expertise in the fields of: • • • • • Structural biology Bioinformatics Monoclonal antibodies and recombinant vaccines Diagnostics Pharmaceuticals For full details of our wide range of technology practices and our comprehensive services portfolio please visit www.cullens.com.au or contact Dr Clarissa Wynne on 07 3011 5555 or firstname.lastname@example.org LabTech Systems develops laboratory automation technologies for the life sciences industry. The company was founded in 2004 and listed on the ASX in 2006 (ASX: LBT). In 2007 LabTech Systems partnered with French healthcare giant bioMérieux to commercialise its first product, now known as the PREVI™ Isola. This revolutionary robotic system for the automation of microbiology processing incorporates LabTech Systems” MicroStreak® technology and was launched into global pathology markets in 2008. The company is working to extend its product pipeline in the laboratory automation arena, a sector that is expected to grow substantially over the next decade. For more information please see www.labtechsystems.com Level 2, 153 Flinders Street Adelaide SA 5000 Telephone: +61 (0)8 8227 1555 70 Australasian BioTechnology Volume 19 • Number 2 • July 2009